Treatment of stable angina
1University of Oklahoma Health Sciences Center, Oklahoma City, USA. udhothadani@ouhsc.edu
Insights
For stable angina pectoris, established treatments reduce symptoms and improve outcomes. However, whether anti-anginal drugs impact adverse clinical events remains unknown, necessitating further research.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Stable angina pectoris is primarily caused by atherosclerotic narrowing of coronary arteries, leading to myocardial ischemia.
- Nonobstructive plaques in coronary arteries pose a risk for acute coronary syndromes.
- Current treatment focuses on symptomatic relief and reducing adverse outcomes like coronary death and myocardial infarction.
Purpose of the Study:
- To investigate the impact of established medical therapies on reducing adverse clinical outcomes in patients with stable angina pectoris.
- To determine if anti-anginal drugs (beta-blockers, long-acting nitrates, calcium channel blockers) affect adverse outcomes in stable angina.
- To evaluate the superiority of suppressing ambulatory myocardial ischemia versus symptom-relief pharmacologic therapy.
Main Methods:
- Review of established treatments including smoking cessation, aspirin, lipid management, and blood pressure control.
- Analysis of the role of beta-blockers and angiotensin-converting enzyme inhibitors in patients with reduced left ventricular function.
- Examination of recent trials evaluating ambulatory ischemia suppression and anti-anginal agent efficacy on outcomes.
Main Results:
- The benefits of smoking cessation, aspirin, lipid control, and hypertension management in reducing adverse outcomes are well-established.
- Beta-blockers and ACE inhibitors are beneficial for patients with diminished left ventricular systolic function.
- The effect of anti-anginal drugs on adverse clinical outcomes in stable angina remains undetermined.
Conclusions:
- While several interventions reduce symptoms and improve outcomes in stable angina, the specific impact of anti-anginal drugs on adverse events is unknown.
- Further research is needed to establish whether suppressing ambulatory ischemia with anti-anginal agents or revascularization is superior to symptom-focused pharmacologic therapy.
- Emerging techniques for refractory angina require validation through large randomized clinical trials.
Abstract:
Severe atherosclerotic narrowing of one or more coronary arteries is responsible for myocardial ischemia and angina pectoris in most patients with stable angina pectoris. The coronary arteries of patients with stable angina also contain many nonobstructive plaques, which are prone to fissures or rupture resulting in presentation of acute coronary syndromes (unstable angina, myocardial infarction, sudden ischemic death). In addition to symptomatic relief of symptoms and an increase in angina-free walking time with antianginal drugs or revascularization procedures, the recent emphasis of treatment has been to reduce adverse clinical outcomes (coronary death and myocardial infarction). The role of smoking cessation, aspirin, treatment of elevated lipids, and treatment of high blood pressure in all patients and of beta-blockers and angiotensin-converting enzyme inhibitors in patients with diminished systolic left ventricular systolic function in reducing adverse outcomes has been well established. What is unknown, however, is whether any anti-anginal drugs (beta-blockers, long-acting nitrates, calcium channel blockers) effect adverse outcomes in patients with stable angina pectoris. Recent trials evaluated the usefulness of suppression of ambulatory ischemia in patients with stable angina pectoris, but it remains to be established whether suppression of ambulatory myocardial ischemia with antianginal agents or revascularization therapy is superior to pharmacologic therapy targeting symptom relief. Patients who have refractory angina despite optimal medical treatment and are not candidates for revascularization procedures may be candidates for newer techniques of transmyocardial revascularization, enhanced external counterpulsation, spinal cord stimulation, or sympathectomy. The usefulness of these techniques, however, needs to be confirmed in large randomized clinical trials.
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:27Coronary Artery Disease V: Interprofessional Care
01:27Angina II: Classification
01:29Angina III: Clinical Manifestations and Assessment
01:26Angina IV: Management
01:20Angina V: Nursing Management